CFO
ALNY icon

CVA Family Office’s Alnylam Pharmaceuticals ALNY Stock Holding History

CVA Family Office’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.9K Buy
96
+4
+4% +$1.21K ﹤0.01% 722
2026
Q1 		$30.4K Buy
92
+33
+56% +$11.2K ﹤0.01% 700
2025
Q4 		$23.5K Sell
59
-3
-5% -$1.33K ﹤0.01% 672
2025
Q3 		$28.3K Buy
62
+1
+2% +$407 ﹤0.01% 633
2025
Q2 		$19.9K Buy
61
+24
+65% +$6.64K ﹤0.01% 687
2025
Q1 		$9.99K Buy
37
+12
+48% +$3.08K ﹤0.01% 793
2024
Q4 		$5.88K Buy
25
+19
+317% +$5K ﹤0.01% 861
2024
Q3 		$1.65K Buy
+6
New +$1.56K ﹤0.01% 1004
2024
Q2 		– Sell
-3
Closed -$448 – 1277
2024
Q1 		$448 Buy
+3
New +$500 ﹤0.01% 1033
2023
Q3 		– Sell
-15
Closed -$2.85K – 255
2023
Q2 		$2.85K Hold
15
– – ﹤0.01% 860
2023
Q1 		$3K Buy
15
+5
+50% +$1.05K ﹤0.01% 828
2022
Q4 		$2.38K Buy
10
+5
+100% +$1.07K ﹤0.01% 815
2022
Q3 		$1K Sell
5
-5
-50% -$954 ﹤0.01% 832
2022
Q2 		$1K Hold
10
– – ﹤0.01% 852
2022
Q1 		$2K Buy
+10
New +$1.52K ﹤0.01% 860

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CVA Family Office's ALNY Position: Q2 2026 in Review

CVA Family Office increased its Alnylam Pharmaceuticals (ALNY) stake by 4.3% in Q2 2026, buying an estimated $1.21K and bringing the position to 96 shares worth $28.9K. The position accounts for ﹤0.01% of the portfolio, ranked #722.

CVA Family Office first reported a position in ALNY in Q1 2022 and has held it in 15 quarters since. The position peaked at $30.4K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • CVA Family Office held 96 shares of Alnylam Pharmaceuticals worth $28.9K as of Q2 2026.
  • CVA Family Office bought 4 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.21K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #722 holding.
  • CVA Family Office first reported a position in Alnylam Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • CVA Family Office's Alnylam Pharmaceuticals position peaked at $30.4K in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.